FDA head urges probe of agency’s dealings with Biogen, maker of controversial new Alzheimer’s drug

FDA acting commissioner Janet Woodcock acknowledged in a letter to Christi A. Grimm, the acting inspector general of the Department of Health and Human Services, that there has been “significant attention and controversy” surrounding the approval of Aduhelm, which is manufactured by Biogen, a Cambridge, Mass., biotech company. In particular, she said, concerns continue to be raised about the agency’s contacts with Biogen, including “some that may have occurred outside of the formal correspondence process.”

View original article here Source

Related Posts